{"entity":{"id":"nct06384807","kind":"trial","name":"A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Cemiplimab in advanced solid tumours, run by Biohaven Therapeutics Ltd., now recruiting.","summary":"A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06384807 by Biohaven Therapeutics Ltd., with 500 participants planned, started 2024-04-22 and due to reach its primary completion in 2028-02. Interventions recorded: BHV-1510 and Cemiplimab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06384807","url":"https://clinicaltrials.gov/study/NCT06384807"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["cemiplimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06384807","phase":"1/2","setting":"A Phase 1/2, First in Human, Dose Escalation and Dose Expansion Study of BHV-1510 (Previously PBI-410) as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumors","sponsor":"Biohaven Therapeutics Ltd.","enrolled":500,"outcomes":[]},"route":"/trials/nct06384807/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/"}]}}